<DOC>
	<DOCNO>NCT01367145</DOCNO>
	<brief_summary>The principal aim study determine effect n3-PUFA top standard therapy surrogate marker disease severity and/or prognosis patient PAD . Treatment duration 3 month , final follow-up plan 6 month inclusion . Primary outcome parameter endothelial function assess flow-mediated vasodilation use brachial artery ultrasound . Secondary outcome measure comprise maximum pain-free treadmill walk distance , pulse wave velocity , whole blood viscosity , platelet activation plasma marker inflammation .</brief_summary>
	<brief_title>OMEGA-3-Polyunsaturated Fatty-Acids ( N3-Pufa ) In Patients With Peripheral Arterial Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Severity disease : Rutherford category II III moderate severe Stable intermittent claudication Ankle Brachial Index &lt; 0.9 Age â‰¥18 year Adequate PAD therapy accord current AHA guideline Current treatment Omacor fish oil product Planned vascular intervention Known hypersensitivity study drug Rest pain ischemic ulcer Exercise tolerance limit factor PAD Inability perform treadmill test Dual antiplatelet therapy ( aspirin clopidogrel ) Previous myocardial infarction Known liver disease , except fatty liver Known bleed diathesis Women childbearing potential practice safe contraception method Current participation another intervention study . Previous participation another study intervention within last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>OMEGA-3 polyunsaturated fatty-acids</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Endothelial Function</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Platelet Function</keyword>
</DOC>